Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...

COVID is tied to a greater prevalence of some neuro-ophthalmic complications than is influenza, but COVID vaccines are linked ...

US FDA approves Celltrion’s Eydenzelt biosimilar referencing Eylea to treat wAMD, macular edema following RVO, DME and diabetic retinopathy: Incheon, South Korea Monday, October ...

Considering this knowledge of the retina, the investigators conducted a study in which the goals were to detect and quantify ...

Elderly people living on the Sunshine Coast who need eye injections in order to maintain their sight are having to pay out of ...

Celltrion said Friday that its eye disease treatment Eydenzelt won approval from the U.S. Food and Drug Administration (FDA), ...

Early and aggressive treatment of dry eye disease can prevent progression and preserve ocular health, especially in glaucoma ...

Biopharmaceutical company Celltrion on Friday said its biosimilar for eye diseases has received approval for sale in the US ...

South Korea-based Celltrion on Friday announced that the US Food and Drug Administration (FDA) has approved Eydenzelt ...

Novartis'sBeovu matched Regeneron'sEylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said on Monday, after early safety stumbles for the medicine in another ...

Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease ...

Sony has expanded its sports business portfolio by acquiring StatSports, one of the world’s leading GPS wearable technology ...